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Metabolism as a Predictor of Disease
Susceptibility
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Polymorphisms in many xenobiotic metabolizing enzymes occur leading to variation in the level of enzyme expression in vivo. Enzymes showing
such polymorphisms include the cytochrome P450 enzymes CYPlAl, CYP1A2, CYP2A6, CYP2D6, and CYP2E1 and the phase two metabolism
enzymes glutathione S-transferase Ml (GSTMI) and arylamine N-acetyltransferase 2 (NAT2). In the past, these polymorphisms have been studied by
phenotyping using in vivo administration of probe drugs. However, the mutations which give rise to several of these polymorphisms have now been
identified and genotyping assays for polymorphisms in CYPIA1, CYP2A6, CYP2D6, CYP2E1, GSTMI, and NAT2 have been developed. Specific phe-
notypes for several of the polymorphic enzymes have been associated with increased susceptibility to malignancy, particularly lung and bladder can-
cer, and Parkinson's disease. These associations are likely to be due to altered activation or detoxication of chemicals initiating these diseases,
including components of tobacco smoke and neurotoxins. The substrate specificity and tissue distribution of polymorphic enzymes implicated in dis-
ease causation discussed with particular reference to previously described disease-phenotype associations.-Environ Health Perspect Vol 102(Suppl
9):55-61 (1994)
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Introduction
There is considerable variation in expres-
sion ofxenobiotic-metabolizing enzymes in
the general population. This variability is
due, at least in part, to the presence of
genetic polymorphisms where mutations in
the wild-type gene result in the synthesis of
enzymes with impaired activity. Individuals
expressing one or more of these mutated
enzymes may differ from normal individu-
als in their susceptibility to certain diseases
where exposure to xenobiotics is a possible
cause. There is now clear evidence at the
metabolic level for polymorphisms in the
cytochrome P450 enzymes CYPlA1,
CYP1A2, CYP2A6 and CYP2D6 and in N-
acetyltransferase 2 (NAT2) and glutathione
S-transferase MI (GSTMI) which carry out
phase 2 conjugation reactions. In the case of
CYP2D6, NAT2, and GSTMI, the genetic
basis of the polymorphism is also well
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understood. There is also evidence at the
genetic level for a polymorphism in the
enzyme CYP2E1. As summarized in Table
1, simple genotyping assays have been
developed for a number of these polymor-
phisms. Associations between specific phe-
notypes for certain polymorphic enzymes
and susceptibility to cancer, particularly
lung and bladder cancer, Parkinson's dis-
ease, and the autoimmune disease systemic
lupus erythematosus have been described.
These associations may be due to differ-
ences in the ability of the various enzyme
phenotypes to activate or detoxicate chemi-
cal toxins or, alternatively, to linkage dise-
quilibrium where a particular allele coding
for another gene with a direct role in deter-
mining disease susceptibility shows genetic
linkage with an allelic variant ofthe xenobi-
otic-metabolizing enzyme.
This article considers associations
between particular metabolic phenotypes
and disease susceptibility, with particular
emphasis on methods for determining
genotypes. The relevance of the enzyme
polymorphism-disease associations from
what is known regarding substrates and tis-
sue-specific expression is also considered.
However, it should be noted that metabo-
lism at the site of the tumor may not be
essential because many carcinogens may
migrate to other tissues following metabo-
lism in the liver (1).
CYPlAl
CYPIAI metabolizes a range of polycyclic
aromatic hydrocarbons including benzo-
[a]pyrene and is inducible by various aro-
matic hydrocarbons which act by binding
to the Ah receptor, a transcriptional activa-
tor of CYPlAI. There appears to be little
significant constitutive CYPlAl expression
in human liver but the enzyme is detectable
in lung tissue from smokers (2). An appar-
ent polymorphism with respect to
inducibility of CYPlAI has been detected
by use of an in vitro assay of lymphocytes
which can classify individuals as high or
low inducers with 3-methylcholanthrene
(3). In two studies, the high inducibility
phenotype was found to be more common
among lung cancer patients than in a group
ofsmoking controls (3,4). However, other
workers (5-7) have failed to reproduce
these findings.
Association of a CYPlAl genotype
detectable by restriction fragment length
polymorphism (RFLP) analysis using the
enzyme MspI with increased susceptibility
to lung cancer, particularly squamous cell
carcinoma, among smokers has been
reported for a Japanese population (8).
However, no such association was detected
in a similar study of a Norwegian popula-
tion (9). The MspI polymorphism has
recently been demonstrated to be linked to
an amino acid substitution in the heme-
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Enzyme Polymorphism orallelicvariant Assay Reference
CYPlAl In 3-flanking region RFLPanalysiswith Mspl Kawajiri etal. (8)
Ato G (Val462to lie) Allele-specific PCR Hayashi etal. (10)
CYP2A6 CYP2A6v(T48,toA, G60toA) Allele-specific PCR Yamano etal.(18)
Dalyetal. (unpublished)
CYP2D6 CYP2D6A(deletion of PCR(allelespecific or Dalyetal. (31);
A2637 in exon 5) with Hpall digest)- Brolyetal. (32);
Smith etal.(41)
CYP2D6B(G 933to A) PCR(with BstNI digestor Dalyetal.(31);
allele-specific) Brolyetal. (32);
Smith etal. (41)
CYP2D6D(deletion of CYP2D6) RFLPanalysis withXbal Dalyetal.(31);
Brolyetal. (32)
Skoda etal. (76)
CYP2E1 Polymorphism in intron 2 RFLPanalysiswith Dral Uematsu(49)
Several point mutations in PCRwith Rsal orPstl digest Hayashi etal. (50)
5-flanking region
GSTMI Null allele(deletion ofGSTM4 RFLPanalysis with EcoRI or Seinegard etal.(53)
BamHI orPCR(no productfor GSTMI) Zhong etal.(60)
Brockmoller etal.(59)
NAT2 Ml (T341 toC,C481 toT,A803toG) PCR (with Kpnl digestorallele-specific) Hickman andSim(66)
Blum etal. (67)
M2(C94toT,G59,toA) PCR(with Taql digestorallele-specific) Hickman and Sim(66)
Blum etal. (67)
M3 (G857toA) PCR(with BamHl digestorallele-specific) Hickman and Sim(66)
Blum etal.(67)
binding region of the enzyme (10). The
base change which gives rise to this substi-
tution can be readily detected by an allele-
specific polymerase chain reaction (PCR)
assay. The MspI genotype apparently asso-
ciated with increased lung cancer suscepti-
bility also appears to cosegregate with the
high inducibility-phenotype for CYPIA1
(11). In view ofthe expression ofCYPlAI
in lung tissue and the nature of its sub-
states, further studies on the role of poly-
morphismsinthis enzyme inrelation to lung
cancersusceptibility appearappropriate.
CYP1A2
CYPIA2 is known to activate arylamine
procarcinogens (12). There is evidence that
it activates tobacco smoke condensate to a
genotoxic product (13) and, in lymphoblas-
toid cells stably expressing this gene, a con-
siderably increased mutation rate and
decreased cell survival compared with the
wild-type has been observed on exposure to
the tobacco smoke-specific nitrosamine 4-
(methylnitrosamino)- 1-(3-pyridyl) -1-
butanone (NNK) (14). Although expressed
constitutively in liver, CYP1A2 has not
been detected in lung (15) and it is unclear
whether CYP1A2 expression is a risk factor
for lung cancer development. However,
tobacco-derived arylamines may undergo
activation by CYP1A2 in the liver and play
a role in the initiation of bladder carcino-
genesis (16). Using caffeine as a probe
drug, a polymorphism for CYP1A2 has
been detected in three separate populations.
Within each of these populations caffeine
metabolism in nonsmokers showed a tri-
modal distribution with 12 to 13% ofsub-
jects studied dassified as slow metabolizers
ofcaffeine (17). Among smokers consider-
able variability in levels of metabolism was
also seen but the distinction between phe-
notypes was blurred, presumably due to
induction of CYPIA2 (17). The genetic
basis of this apparent polymorphism is not
yet understood.
CYP2A6
CYP2A6 is a constitutive cytochrome P450
which is expressed in human liver at vari-
able levels (18). This enzyme may also be
expressed in other tissues, including nasal
tissue (19). CYP2A6 carries out 7-hydrox-
ylation of coumarin but also appears to
activate certain procarcinogens, including
hexamethylphosphoramide (19), N-
nitrosodimethylamine (20), NNK (14)
and aflatoxin B1 (21). Using coumarin as a
probe drug, the formation of 7-hydroxy-
coumarin has been investigated in a group
ofvolunteers. Considerable variation in the
percentage of drug excreted as 7-hydroxy
metabolites has been observed with levels
ofconversion varying from 10 to 120% of
the dose (22). A variant cDNA (CYP2A6v)
which lacks coumarin 7-hydroxylase activ-
ity and has only three nucleotide differ-
ences compared with the wild-type
CYP2A6, one of which gives rise to the
amino acid substitution Leu160 to His, has
been isolated (18). DNA samples from the
volunteer group previously investigated by
coumarin phenotyping have been analyzed
for the presence of the mutation which
gives rise to the amino acid substitution
using an allele-specific PCR assay (Daly
AK, Vaz A, Cholerton S, and Idle JR,
unpublished data). The variant allele was
detected at a frequency of0.02 and was not
present in four subjects who showed recov-
ery of coumarin metabolites of less than
40%. However, three subjects were het-
erozygous for the variant allele and showed
recoveries ofmetabolites of 59.7%, 61.8%
and 79.5% (mean 67%). These values were
significantly different from the mean recov-
eries of the remaining population (90.1%,
n = 104) on the basis ofunpaired t-testing
(p = 0.02). This suggests that the
CYP2A61CYP2A6v genotype leads to some
impairment of coumarin metabolism. It is
likely that other mutations in CYP2A6
associated with poor metabolism of
coumarin remain undetected.
CYP2D6
CYP2D6 metabolizes a variety of drugs
used therapeutically, including antiarryth-
mics, antidepressants, and neuroleptics
(23). There is also evidence that CYP2D6
can metabolize the neurotoxins 1,2,3,4-
tetrahydroisoquinoline (TIQ) (24) and 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) (25). Studies of lymphoblastoid
cells stably transfected with CYP2D6 indi-
cate that the tobacco-specific nitrosamine
NNK is a CYP2D6 substrate (14),
although in inhibition studies NNK
showed little effect on metoprolol metabo-
lism (26). CYP2D6 is expressed constitu-
tively in human liver (27) and no inducers
of this enzyme have been identified.
Studies on the expression of CYP2D forms
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Figure 1. Northern blot analysis of CYP2D expression in
rat and human tissues.The blot was probed with a
CYP2D6 cDNA probe. Lane 1, 5 mg poly A+ RNAfrom rat
lung; lane 2, 5 mg poly A+ RNA from rat liver; lane 3, 40
mg total RNA from human lymphoblastoid cells; lane 4,
40 mg rat lung RNA; lane 5, 40 mg rat liver RNA; lane 6,
40mg human lymphoblastoid cell RNA.
in rat tissues have demonstrated readily
detectable levels ofRNA expression in liver
and kidney (28). Expression has also been
detected in human brain by PCR analysis
of a caudate nucleus cDNA library (29).
Using poly A+ RNA from rat liver and
lung, we have recently detected transcripts
which hybridize to a CYP2D6 cDNA
probe in both tissues (Figure 1). However,
the major band approximately 8S in liver is
at least 100-fold more intense than the cor-
responding band in lung. Two other higher
molecular weight transcripts are also
detected in liver but the larger and stronger
ofthese is not detected in lung. It is not yet
known whether CYP2D6 transcripts are
detectable in human lung. No CYP2D
transcripts were detected in a human lym-
phoblastoid cell line (Figure 1).
CYP2D6 is polymorphic and 3.2 to
11.5% of individuals in various European
populations lack this enzyme activity (30).
These individuals, termed poor metaboliz-
ers (PMs) have been identified in the past
by administration ofthe drug debrisoquine,
sparteine, or dextromethorphan followed by
analysis of urinary metabolites. A number
of inactivating mutations in CYP2D6have
now been identified and are summarized in
Table 1. The CYP2D6A and CYP2D6B
alleles can be detected by PCR-based assays
using either restriction digests or allele-spe-
cific primers. The CYP2D6D allele repre-
sents complete deletion of the coding gene
and, at present, can only be detected by
RFLP analysis with the enzyme XbaI. In
addition to the CYP2D6D allele which is
represented by a 13-kb band on RFLP
analysis with XbaI, a separate band of 11
kb, which is also associated with the PM
phenotype (31) and probably represents
another type of large deletion, can be
detected in some individuals.
By combination of PCR and RFLP
assays, 95% of European phenotypic PMs
can be identified as genotypic PMs (31-
33). The remaining 5% of PMs are likely
to have rare mutations in one or both alle-
les. In a sequencing study on DNA from a
subject classified phenotypically as a PM
but with an apparent heterozygous geno-
type, we have detected a single base substi-
tution (G2064 to A) in exon 4 of CYP2D6
which results in substitution of Glu for
Gly. Using allele-specific PCR, approxi-
mately 100 subjects have been screened for
the presence ofthis mutation; but in addi-
tion to the original subject studied, the
mutation has only been detected in one
other individual (also a PM), giving an
allele frequency of0.01.
In the past, phenotyping studies using
debrisoquine or another CYP2D6-specific
probe drug have suggested associations
between particular phenotypes and disease
susceptibility. As discussed above, there is
evidence that CYP2D6 may activate the
procarcinogen NNK while detoxicating
certain neurotoxins. These findings as well
as increasing evidence for extrahepatic
expression of CYP2D6 may account for
these phenotype-disease assocations. Two
independent studies oflung cancer patients
have demonstrated a reduced frequency of
PMs and a generally increased level of
metabolism ofdebrisoquine comparedwith
several types of control group (34,35).
Similarly, among cases of aggressive blad-
der cancer, a reduced frequency ofthe PM
phenotype was observed (36). A study of
Parkinson's disease patients observed an
increased frequency ofPMs compared with
controls (37), although some ofthese find-
ings were later ascribed to interference by
other drugs in the debrisoquine phenotyp-
ing procedure (38). An increased frequency
of the autoimmune disease systemic lupus
erythematosus among poor metabolizers
has also been reported (39). With the
advent of genotyping techniques, studies
on disease susceptibility can be carried out
with increased accuracy, since there is no
possibility ofinterference by other drugs in
the procedure and the majority ofsubjects
can be accurately categorized as homozy-
gous or heterozygous extensive metaboliz-
ers or PMs.
Two studies on CYP2D6 genotypes
among Parkinson's disease patients have
recently emerged (40,41). In the first,
CYP2D6 genotypes were analyzed for 53
Parkinson's disease patients and 72 con-
trols. A small but not statistically signifi-
cant increase was observed in the
percentage of heterozygous extensive
metabolizers but when allele frequencies
between the two groups were compared,
the CYP2D6B allele frequency was
increased from 10.4% in the control group
to 21.65% among cases, representing a rel-
ative risk of2.7 (40). These findings could
be explained by linkage disequilibrium
with an association between CYP2D6Band
an allele from another gene with a role in
determining susceptibility to this disease.
In a study of a larger population (41), an
increase in frequency of the PM genotype
from 5.0 to 11.8% was observed with a rel-
ative risk of 2.54. There is a need for fur-
ther studies of this type, particularly to
investigate the possibility that it may be
early-onset Parkinson's disease in particular
that is associated with the PM phenotype
due to the role ofCYP2D6 in the metabo-
lism ofneurotoxins.
A study on the relationship between
CYP2D6genotype and susceptibility to a
number of different types of cancer has
recently been reported (42). In this study,
CYP2D6Ballele distributions for 1635 can-
cer patients and an unmatched control
group of 720 random volunteers were
examined. No significant difference in the
frequency of the CYP2D6B allele between
lung cancer patients and controls was
observed. Some statistically significant dif-
ferences in genotype frequencies between
patients and controls were obtained for
other tumors, including an increase in the
percentage of PMs among leukemia
patients. Although interesting, this study is
very preliminary and there is a need to carry
out well-designed case-control studies using
genotyping methods which detect a higher
percentage of PMs and heterozygotes and
are validated by preliminary metabolic phe-
notyping of the study population.
Definitive answers on the role ofpolymor-
phism in CYP2D6 in determining disease
susceptibility should soon be available.
CYP2E1
CYP2E1 metabolizes nitrosamines, includ-
ing the procarcinogens N-nitrosodimethy-
lamine and N-nitrosopyrrolidine (43), the
tobacco smoke component 3-hydroxypyri-
dine (44) and many common organic sol-
vents including benzene (43). This enzyme
is inducible by ethanol, and thus alcohol
consumption may influence carcinogenesis
involving CYP2E1. The majority of expres-
sion in humans is in liverwhere interindivid-
ual variability in levels of expression may
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occur (45). Expression has also been
detected in rat lung (46), rabbit nasal tissue
andkidney (47), and human leucocyte (48).
A polymorphism in intron 2 of the
human CYP2EJ gene is detectable by
RFLP analysis with DraL. Genotyping
analysis of a lung cancer patient group
showed a significantly reduced incidence of
a rare genotype among cases compared
with a control group (49). Two linked
polymorphisms in the 5'-flanking region of
CYP2EI affecting levels of transcription
have also been identified (50). PCR assays
for analysis of these polymorphisms have
been described but have not yet been
applied to studies on disease susceptibility.
Glutathione S-Transferase p
Glutathione S-transferases are a multigene
family ofenzymes which conjugate xenobi-
otics with glutathione (51). In the case of
the near-neutral family, a polymorphism
has been detected at the human GSTI
locus which codes for glutathione S-trans-
ferase (GSTMI). Three different allelic
variants have been detected, with two of
these, GSTMI*A and GSTMI*B, coding
for enzymes of similar catalytic activity
(52) whereas GSTMI 0 (the null allele)
produces no catalytically active enzyme and
may represent complete deletion of the
coding gene (53). In most racial groups, 40
to 50% ofsubjects are homozygous for the
null allele and lack GSTM (54). GSTMI is
expressed in a variety of human tissues
including liver, leucocyte, kidney, and
stomach (55). Expression has also been
detected in lung but this enzyme appeared
to have a faster mobility than the liver form
in Western immunoblot experiments and
did not appear polymorphic (56).
Substrates for GSTMI include trans-stil-
bene oxide and benzo[a]pyrene-4,5-oxide
(51). GSTMI phenotyping can be carried
out in leukocytes by assay for enzyme activ-
ity towards trans-stilbene oxide (57) or by
immunoassay (58). More recently, geno-
typing assays have been developed using
either RFLP analysis with EcoRI or BamHI
(53) or PCR assays (59) where absence of
GSTMI amplification indicates that the
subject is homozygous for the null allele.
Phenotyping studies on lung cancer
patients have indicated that lack ofGSTMI
activity is associated with an increased risk
of lung cancer-particularly adenocarci-
noma-development among smokers (57).
More recently using both genotyping by
RFLP analysis and phenotyping by
radioimmunoassay, no significant differ-
ence in GSTMI expression was detected
between a lung cancer group and a control
group but a small but statistically signifi-
cant increase in lack ofGSTMI expression
was seen among a subgroup of patients
with squamous carcinoma (60). In a recent
case-control study on smoking-related can-
cers (mainly lung cancers) using phenotyp-
ing by enzyme activity measurements, there
was no overall difference in the percentage
ofsubjects with low levels ofenzyme activ-
ity (GSTMI negative) between cancer
patients and controls but a small increase
in the percentage ofGSTMI-negative sub-
jects was detected in a subgroup of heavy
smokers with smoking-related cancers
(61). At present, therefore the relationship
between GSTMI expression and lung can-
cer susceptibility remains unclear.
Aylarie N-Aceltransferase 2
Two forms of N-acetyltransferase (NAT1
and NAT2) carry out N-acetylation ofary-
lamines and certain other reactions such as
aacetylation (62). Expression ofNAT2 is
polymorphic and about 50% ofCaucasians
lack this enzyme activity and are termed
slow acetylators (63). In addition to
metabolizing a group of therapeutically
important drugs, NAT2 also acetylates ary-
lamines including benzidine, 2-aminofluo-
rine and I-naphthylamine (16). NAT has
been detected in human liver (62) and
colon (64). In rabbits, NATis expressed in
a variety of tissues including duodenum,
lung, kidney, and bladder mucosa (63).
Slow acetylators are detectable by phe-
notyping with a number of probe drugs
including caffeine and sulphamethazine
(63). Recently, the NAT2 gene has been
cloned and sequenced and a number of
point mutations associated with the slow
acetylator phenotype identified. Three vari-
ant alleles (Table 1) which lack NAT activ-
ity in vitro have been identified in several
independent studies (65-68). Each variant
contains one or more base substitutions
with at least one of these introducing an
amino acid change. The presence of the
variant alleles can be readily detected by
PCR assays using either digestion ofprod-
uct with a restriction enzyme or allele-spe-
cific methods (66,67), allowing positive
identification of greater than 90% of all
slow acetylators.
The association between acetylation
phenotype and disease susceptibility has
received considerable attention. Slow acety-
lators appear to be at increased risk for
development ofsystemic lupus erythemato-
sus ifgiven certain NAT2 substrates thera-
peutically (63). In addition, susceptibility
to certain types ofcancer involving chemi-
cal carcinogenesis may be related to acety-
lator phenotype. The majority of bladder
cancer is likely to be related to either occu-
pational exposure or cigarette smoking
(69). In a case-control study of occupa-
tionally induced bladder cancer, a large
excess of slow acetylators was detected in
the occupationally exposed group and an
odds ratio of 16.7 calculated for risk ofdis-
ease development in slow acetylators (70).
However, this study found no relationship
between acetylator phenotype and develop-
ment ofsmoking-related bladder cancer in
the absence of confirmed occupational
exposure to arylamines and subsequent
independent studies have generally con-
firmed these findings (71-73).
Trace amounts of arylamines may be
formed during normal cooking of food.
Since these compounds are likely NAT
substrates, the possibility that acetylator
phenotype might relate to susceptibility to
colon cancer was investigated (74,75). An
increased frequency of the rapid acetylator
phenotype was observed among a group of
colorectal cancer patients. The difference in
relationship between acetylator phenotype
and susceptibility to bladder and colon
cancer may be due to NAT primarily act-
ing as a detoxicating enzyme in bladder
while in the colon, N-oxidized arylamines
may undergo activation by N- and 0-
acetylation reactions catalyzed by NAT
(16). Although the majority ofslow acety-
lators can now be identified by genotyping,
studies on genotype-disease susceptibility
relationships have not yet been reported.
Conclusion
A number ofindependent studies have now
demonstrated the importance of polymor-
phisms in xenobiotic metabolism as risk
factors in the development ofdiseases asso-
ciated with chemical exposure. In parallel
with these studies, a clearer understanding
of the genetic basis of the polymorphisms
has emerged, together with more accurate
and less invasive methods for screening of
populations. Many of the previous studies
can be now be more accurately replicated
and extended and, in addition, the influ-
ence ofmultiple polymorphisms on disease
susceptibility examined.
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